Category: newsletters

Hot Topics in Tech | September 2018 Newsletter | Maxval

This issue covers cardiovascular diseases and discloses the technological categories and products related to the use of renal denervation approach for managing hypertension. It also talks about the three main categories of Artificial Intelligence namely Artificial Narrow Intelligence (ANI), Artificial General Intelligence (AGI), and Artificial Super Intelligence (ASI). They influence human life in the form of automated cars, virtual assistants, image recognition software, robotics, games, life science and so on. Read more on this report.

Continue reading

Hot Topics in Tech | August 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and blockchain technology industries. We have highlighted Illumina’s Q2 results and provided some
insights about the company alongwith a quick run-through of the firm's recent collaborations in China. Illumina reported a revenue of $830 million in Q2 which is a 25% increase compared to $662 million in the same quarter of 2017. Illumina’s biggest advantage over its competitors lies in its technology diversification.

Continue reading

Hot Topics in Tech | June 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and cloud-tech industries. We have talked about the FDA's approval of tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.), a CD19-directed genetically modified autologous T-cell immunotherapy, to include treatment of patients with relapsed or refractory large B-cell lymphoma. Tisagenlecleucel is the only CAR T-cell therapy to receive FDA approval for two distinct indications. The report includes a chart of major commercial players in the CAR T-cell space and a Year-on-Year trend on the number of patents and patent applications from 2012 to 2018.

Continue reading

Recent advances in Life Sciences | May 2018 Newsletter | MaxVal

The article presents a base editing approach to expand the scope and efficiency of CRISPR mediated genome editing.

Continue reading

Recent advances in Diabetes Management | April 2018 Newsletter | MaxVal

The article addresses Medtronic’s recent FDA approval of the Guardian™ Connect Continuous Glucose Monitoring (CGM) system. A brief overview of all the clinical studies related to CGM has been presented.

Continue reading